Notable

Our research is focused on developing novel Presponse™ therapeutics so physicians will know if their patient is likely to benefit before they commit to treatment. We know that getting the right treatment to the right patient the first time is critical to success in the fight against cancer. Visit notablelabs.com/research for more information. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

Notable Labs team members were energized by the response to our poster at the 12th annual meeting of the Society of Hematologic Oncology (SOHO 2024)! We were privileged to join cutting-edge research companies presenting the latest breakthrough research. We remain committed to being the leader in predictive medicine and to revolutionize how patients seek and receive treatments that work best for them. https://lnkd.in/ejhYFcrH    Glenn Michelson; Scott Houston; Chris Leonardi; Markus Lacher; Joseph Wagner #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Our mission is to develop therapeutics that work predictably for people fighting cancer. For many people, a cancer diagnosis is quickly followed by nerve-wracking choices about treatment options. Notable is dedicated to developing therapeutics so that physicians will know whether a patient is likely to benefit before they recommend a treatment.  #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

Don't miss the Notable Labs poster, “Revival of the Polo-Like Kinase 1 (PLK1) Inhibitor Volasertis In Relapsed/Refractory Acute Myeloid Leukemia,” presented at the twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.   Glenn Michelson; S. Houston; Chris Leonardi; Markus Lacher; Joseph Wagner #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Our team at Notable Labs is looking forward to attending the twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas. We look forward to learning about the latest breakthroughs in the research and treatment of patients with hematologic malignancies and collaborating in real time with our colleagues. Contact us at https://lnkd.in/eAgN3cFt to set up an appointment. #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

There are more than 300 kinds of cancer and each patient’s cancer is unique. Importantly, it can take months to determine which patients will respond to their treatment and who will need another option. This is time that many patients and their families simply cannot afford. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

Notable is building an innovative environment at the intersection of technology and biology. Our engineers, cell biologists, data scientists, drug developers and diagnostics experts work side-by-side in interdisciplinary teams with the goal of transforming the traditional concept of standard-of-care by pioneering a novel responder-focused approach to drug development. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

Notable is harnessing our predictive medicine platform to build a pipeline of novel therapeutics. By matching the right drug with the right patient, we aim to increase the clinical response rate of the therapeutics in our pipeline while reducing the risk, time and cost of development. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

Our predictive medicine platform employs advanced technology, including flow cytometry and robotic automation, to bio-simulate treatment of each patient’s cancer at the cellular level. Our biological response database provides improved insight into patient response, helping us to identify promising drugs to develop into new therapeutics. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation

Getting the right treatment to the right patient, the first time, is critical for people fighting cancer. By combining existing de-risked drugs with a proprietary predicted responder diagnostic, we're working to ensure that a patient will only receive treatment that is likely to work for them. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch